After an eye injury from trauma, corneal surgery or a chemical burns, corneal tissues and local immune cells (Leukocytes) generate pro-inflammatory cytokines and prostaglandins that initiate acute pain and increase tissue permeability. Chemokine concentrations, to attract circulating Leukocytes, are also increased as are levels of adhesion molecules to ensure high levels of Leukocytes remain in the inflamed tissue. These effects can be blocked by activation of CB2 receptors that appear in high numbers after corneal injury so that pain and inflammation are controlled. TA-A001 is a CB2 receptor activator which has been shown to produce rapid analgesia in acute pain models including after topical application to the eye.
Should inflammation not be brought under control, due to an infection, as occurs in Keratitis or Uveitis, or in chronic diseases such as Dry Eye Syndrome and Age Related Macular Degeneration (AMD) a vicious cycle develops whereby Leukocytes numbers remain high as do the levels of tissue destructive superoxide, proteases and hypochlorous acid they release; blindness can result.TA-A001 has been shown to break the cycle by reducing Leukocyte levels and levels of pro-inflammatory cytokines and prostaglandins.
TALLC issues new Corporate Presentation
Dr. Damon Smith at Biotech Show Case
TALLC at the Ophthalmology Innovation Summit
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
© TALLC Inc. 2020